🇺🇸 FDA
Pipeline program

INC280

CINC280X2202

Phase 2 small_molecule completed

Quick answer

INC280 for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials